Innovation at Target Health – Target e*Studio™ Version 2 – EDC Made Simple, Released


Since 1999, Target e*CRF has been used in 25 unique regulatory approvals, including 3 approvals in 2012 (2 FDA; 1 EMA).

Target Health is pleased to announce the release of Target e*Studio™ Version 2. This elegant and innovative software allows CROs/Sponsors to build EDC applications with minimal programming expertise. Additional versions will be released over the next 6 months which should eliminate the need to perform any advanced programming. Of course, we are always there to help. Some of the current features include form and edit check builders, randomization module, drug/supply management, automatic generation of an annotated and blank eCRF, laboratory data upload, bookmarked pdf file of the final eCRF populated with the clinical trial data, eSignatures and integration with Target Encoder. Within the next few months we will be moving the development of applications (studies) to data management and many of our current staff assigned to software testing will be part of the team that will build EDC applications.

Target Health Inc., a full service eCRO, has been developing and using innovative web-based software tools for the paperless clinical trial. These software products provide CROs and Sponsors with a transparent environment and a significant productivity edge. Our business model includes partnering with other CROs in the utilization of our software.

What is our partnership model?

1. Minimal low cost initial investment which includes training

2. We can build or help you build the applications

3. Cost per study is based on study size

4. Hosting included

For more information about Target Health contact Warren Pearlson  212-681-2100  ext. 104). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel or Ms. Joyce Hays. The Target Health software tools are designed to partner with both CROs and Sponsors. Please visit the Target Health Website.


Leave a Reply

You must be logged in to post a comment.